Cell and Gene Therapy Market

Global Cell and Gene Therapy Market Snapshot

• Global Cell and Gene Therapy Market Size in 2026: USD 32.5 Billion
• Global Cell and Gene Therapy Market Size in 2035: USD 158.6 Billion
• Global CAGR from 2026 to 2035: 19.3%
• Cell Therapy is the leading therapy type segment in 2026: 64.5%
• Oncological Disorders is the leading indication segment in 2026: 46.3%
• In Vivo is the leading delivery method segment in 2026: 57.2%
• Hospitals is the leading end user segment in 2026: 47.6%
• North America is the leading region in 2026: 51.1%
• The U.S. Cell and Gene Therapy Market Size in 2026: USD 14.2 Billion, growing at an 18.1% CAGR

What is the Global Cell and Gene Therapy and its Market Size?

The Global Cell and Gene Therapy Market is projected to be valued at USD 32.5 Billion in 2026 and is projected to reach USD 158.6 Billion by 2035, growing at a CAGR of 19.3% during the forecast period.

ℹ To learn more about this report – Download Your Free Sample Report Here

Growth is being propelled by breakthroughs in gene-editing technologies such as CRISPR, expanding viral and non-viral delivery platforms, the rising global burden of oncological and rare genetic disorders, and an accelerating pipeline of allogeneic "off-the-shelf" cell therapies. The maturing regulatory environment, particularly the FDA's collaborative approach to advanced therapy approvals, together with growing investment in cell and gene therapy manufacturing infrastructure, is reshaping how chronic, degenerative, and hereditary diseases are treated.

Use Cases

• Cancer Treatment (CAR-T Therapy): Oncology and hematology centers engineer patient-derived T-cells to recognize and destroy cancer cells, delivering a personalized and potentially curative approach for leukemia and lymphoma.
• Rare Genetic Disorders: Gene therapy developers deliver functional copies of defective genes to correct inherited conditions such as spinal muscular atrophy (SMA) and hemophilia at the molecular level.
• Regenerative Medicine: Hospitals and specialty clinics use stem cell transplantation and related cell therapies to repair damaged tissue, including post-infarction cardiac repair and neuronal regeneration in neurodegenerative disease.
• Immunological Disorders: Research institutions and biotech developers engineer immune cells to treat autoimmune conditions and viral infections, including investigational therapies for HIV and severe combined immunodeficiency (SCID).

Key Takeaways

• Market Size: The Global Cell and Gene Therapy Market is anticipated to be valued at USD 32.5 Billion in 2026 and is forecast to reach USD 158.6 Billion by 2035, expanding at a CAGR of 19.3%.
• Growth Outlook: Market expansion is sustained by rising adoption of gene-editing platforms, growing clinical validation of allogeneic cell therapies, expanding oncology and rare-disease pipelines, and increasing manufacturing capacity for viral vector and cell-processing infrastructure.
• Primary Growth Drivers: Rising prevalence of cancer, rare genetic disorders, and age-related chronic conditions; continued breakthroughs in CRISPR and delivery-vector technology; favorable FDA and regional regulatory support; and growing private and public investment in advanced therapy manufacturing.
• By Therapy Type Analysis: Cell Therapy is projected to lead with an estimated 64.5% share in 2026, supported by its broad application across oncology, autoimmune, and urinary disorders, while Gene Therapy holds an estimated 35.5% share and is expected to post the faster CAGR of roughly 21.8% through 2035 as root-cause genetic correction platforms mature.
• By Indication Analysis: Oncological Disorders are anticipated to hold an estimated 46.3% share in 2026, reflecting the concentration of CAR-T and other cell-based cancer therapies, while Genetic Disorders hold an estimated 22.5% share and are projected to record the fastest CAGR at roughly 22.7%, driven by rising genetic testing and diagnosis awareness.
• By Delivery Method Analysis: In Vivo delivery is expected to command an estimated 57.2% share in 2026 given its broadening use across gene therapy indications, while Ex Vivo delivery holds an estimated 42.8% share, anchored by established CAR-T manufacturing workflows.
• By End User Analysis: Hospitals are expected to lead with an estimated 47.6% share in 2026 owing to their capacity to deliver advanced, closely monitored therapies, while Cancer Care Centers hold an estimated 26.4% share and are projected to grow fastest at roughly 21.4% CAGR as specialized oncology treatment volumes rise.

How AI/Gen AI is Transforming the Cell and Gene Therapy Market?

Advances in gene-editing precision, automated cell-processing, and AI-assisted vector design are reshaping how cell and gene therapies are developed and manufactured. Machine learning tools are increasingly applied to optimize viral vector yield, predict off-target editing effects, and accelerate candidate screening for genetic disorders. Digital manufacturing execution systems are being adopted to standardize autologous and allogeneic cell-processing workflows, reducing batch-to-batch variability and shortening vein-to-vein time for CAR-T therapies. These technologies are also supporting real-world evidence collection for long-term efficacy and safety monitoring required by regulators for advanced therapy medicinal products.

Key Drivers in the Global Cell and Gene Therapy Market

Technological Advancements and Innovations

Rapid advancements in gene editing, particularly CRISPR-based technologies, are transforming the Global Cell and Gene Therapy Market by improving treatment precision, safety, and therapeutic effectiveness. Innovations in viral and non-viral delivery systems are enabling genetic material to reach targeted cells more efficiently while reducing potential adverse effects. Automated manufacturing platforms, improved vector engineering, and advanced cell-processing technologies are also supporting greater production consistency and scalability. These technological developments are gradually reducing manufacturing complexity and accelerating clinical development timelines. Moreover, improved gene modification techniques are expanding applications beyond rare genetic disorders into oncology, neurological diseases, cardiovascular conditions, and autoimmune disorders, supporting sustained global market expansion.

Rising Prevalence of Chronic and Genetic Diseases

The growing prevalence of cancer, inherited genetic disorders, neurological diseases, and other chronic conditions is significantly increasing demand for cell and gene therapies worldwide. Conventional treatments often manage symptoms without addressing underlying disease mechanisms, creating strong demand for potentially curative and disease-modifying therapies. Expanding genetic testing and newborn screening programs are improving identification of patients with inherited disorders, thereby increasing the eligible treatment population. Rising cancer incidence is simultaneously supporting adoption of CAR-T and other engineered cellular therapies. Improved disease awareness, earlier diagnosis, expanding precision medicine programs, and greater healthcare investment are collectively strengthening the clinical need for advanced cell and gene therapy solutions.

Restraints in the Global Cell and Gene Therapy Market

High Development and Treatment Costs

High research, development, manufacturing, and treatment costs remain major barriers to broader adoption of cell and gene therapies. Developing these treatments requires specialized laboratories, sophisticated manufacturing facilities, extensive clinical trials, highly trained personnel, and rigorous quality-control procedures. Personalized therapies such as autologous CAR-T treatments additionally involve complex patient-specific collection, processing, transportation, and administration procedures, increasing overall costs. Commercial therapies can consequently carry substantial prices, creating affordability challenges for patients and healthcare systems. Limited reimbursement coverage and uncertainty surrounding long-term treatment value further restrict accessibility, particularly across developing economies. Manufacturers are therefore pursuing automation, standardized manufacturing, and scalable production technologies to reduce costs.

Regulatory and Logistical Challenges

Complex regulatory requirements and demanding logistics create significant commercialization challenges across the Global Cell and Gene Therapy Market. Regulatory agencies require extensive evidence regarding safety, efficacy, manufacturing consistency, durability, and long-term patient outcomes before approving advanced therapies. Differences between regional regulatory frameworks can further complicate multinational clinical development and commercialization strategies. Autologous cell therapies additionally depend on tightly controlled collection, transportation, manufacturing, and delivery schedules. Maintaining product integrity through specialized cold-chain systems creates operational complexity and increases costs. Manufacturing failures or transportation delays can directly affect patient treatment schedules. Companies must therefore establish robust supply chains, standardized quality systems, regulatory expertise, and specialized treatment networks to achieve commercial scalability.

Growth Opportunities in the Global Cell and Gene Therapy Market

Expansion into Emerging Markets

Emerging markets represent significant opportunities for cell and gene therapy companies as healthcare infrastructure, biotechnology capabilities, and precision medicine investments expand across Asia Pacific, Latin America, and the Middle East. Governments are increasingly supporting genomic research, clinical trials, biotechnology manufacturing, and advanced therapeutic development through funding programs and regulatory reforms. Large patient populations and rising diagnosis of cancer and genetic disorders provide substantial potential demand. Establishing regional manufacturing facilities and partnerships with hospitals, academic institutions, and local biotechnology companies can improve accessibility while reducing logistical costs. As regulatory pathways mature and healthcare spending increases, emerging economies could become important clinical development and commercialization markets.

Advancements in Personalized and Off-the-Shelf Medicine

Development of personalized and off-the-shelf therapies is creating substantial opportunities across the Global Cell and Gene Therapy Market. Autologous treatments enable therapies to be tailored using a patient's own cells, supporting highly targeted treatment for complex cancers and genetic diseases. Meanwhile, allogeneic therapies derived from healthy donors offer opportunities for standardized manufacturing, inventory availability, and faster treatment administration. Advances in gene editing are helping developers reduce immune rejection and improve persistence of donor-derived cells. Combining personalized precision with scalable manufacturing could significantly broaden treatment accessibility. Continued innovation in universal cell platforms may reduce production costs, shorten treatment waiting periods, and support commercial expansion.

Trends in the Global Cell and Gene Therapy Market

Increased Collaboration and Partnerships

Strategic collaborations among pharmaceutical companies, biotechnology firms, academic institutions, contract manufacturers, and research organizations are becoming increasingly important within the Global Cell and Gene Therapy Market. Partnerships allow companies to combine expertise in gene editing, vector development, clinical research, manufacturing, regulatory affairs, and commercialization. Large pharmaceutical companies increasingly collaborate with innovative biotechnology developers to gain access to emerging therapeutic platforms and promising pipelines. Academic institutions also contribute fundamental research and early-stage clinical innovation. Manufacturing partnerships help developers overcome capacity constraints and accelerate commercial readiness. These collaborations distribute development risks, provide additional financing opportunities, shorten development timelines, and strengthen the probability of successfully bringing advanced therapies to patients.

Adoption of Allogeneic Off-the-Shelf Therapies

Allogeneic off-the-shelf cell therapies are emerging as an important trend because they offer potential scalability advantages compared with patient-specific autologous treatments. These therapies use donor-derived cells that can be manufactured in larger batches, stored, and distributed to treatment centers when required. This approach can shorten treatment waiting times and potentially reduce manufacturing costs per patient. Advances in gene editing are helping developers engineer donor cells to minimize immune rejection while maintaining therapeutic effectiveness. Allogeneic platforms are being investigated extensively across oncology and other therapeutic areas. Successful clinical development could improve treatment accessibility, simplify supply chains, increase manufacturing efficiency, and significantly expand eligible patient populations.

Research Scope and Analysis

The Global Cell and Gene Therapy Market is segmented by therapy type, indication, delivery method, and end user. It covers cell and gene therapies for oncological, genetic, cardiovascular, and neurological disorders, using in vivo and ex vivo delivery across hospitals, research centers, and cancer care centers.

ℹ To learn more about this report – Download Your Free Sample Report Here

By Therapy Type Analysis

Cell therapy is expected to dominate the Global Cell and Gene Therapy Market with an estimated 64.5% share in 2026, supported by expanding clinical applications across oncology, autoimmune disorders, regenerative medicine, and other complex conditions. Significant investment in CAR-T therapies, stem cell platforms, and manufacturing infrastructure continues to reinforce segment leadership. Gene therapy is projected to register the faster CAGR of 21.8% during 2026–2035. Growth is driven by its ability to address underlying genetic abnormalities rather than merely managing disease symptoms. Advancements in gene editing, viral vectors, delivery technologies, and genomic diagnostics are expanding gene therapy pipelines and commercial opportunities globally.

By Indication Analysis

Oncological disorders are anticipated to dominate the Global Cell and Gene Therapy Market by indication, accounting for an estimated 46.3% share in 2026. Strong leadership reflects substantial investment in CAR-T therapies, engineered immune cells, gene-modified treatments, and other advanced approaches targeting hematological and solid tumors. Pharmaceutical and biotechnology companies continue expanding oncology pipelines due to significant unmet clinical needs. Genetic disorders are projected to register the fastest CAGR of 22.7% between 2026 and 2035. Expanded genetic screening, improved molecular diagnostics, greater rare disease awareness, and development of therapies capable of correcting disease-causing mutations are accelerating growth across inherited disease applications.

By Delivery Method Analysis

In vivo therapy is projected to dominate the Global Cell and Gene Therapy Market by delivery method, accounting for an estimated 57.2% share in 2026. Its leadership reflects expanding applications where therapeutic genetic material is delivered directly into targeted tissues or cells inside the patient's body. Improvements in viral vectors, nanoparticles, and tissue-targeting technologies are strengthening treatment effectiveness. Ex vivo therapy is expected to represent 42.8% of the market and expand at roughly 18.2% CAGR through 2035. Established CAR-T manufacturing processes, improving cell engineering techniques, and expanding autologous and allogeneic manufacturing capacity continue supporting adoption across oncology and genetic disorders.

By End User Analysis

Hospitals are expected to dominate the Global Cell and Gene Therapy Market by end user, capturing an estimated 47.6% share in 2026. Their leadership is supported by specialized infrastructure, multidisciplinary clinical teams, intensive patient monitoring capabilities, and established treatment pathways required for administering advanced therapies. Hospitals also serve as important sites for clinical trials and post-treatment monitoring. Cancer care centers are projected to record the fastest CAGR of 21.4% through 2035, supported by increasing adoption of CAR-T and other oncology-focused therapies. Their specialized expertise, dedicated treatment facilities, and growing participation in clinical research position cancer centers as increasingly important therapy providers.

The Global Cell and Gene Therapy Market Report is segmented based on the following:

By Therapy Type

• Cell Therapy
  • Stem Cells
  • T Cells
  • Dendritic Cells
  • NK Cells
  • Tumor Cells
• Gene Therapy

By Indication

• Genetic Disorders
• Cardiovascular Disorders
• Neurological Disorders
• Oncological Disorders
• Others

By Delivery Method

• In Vivo
• Ex Vivo

By End User

• Hospitals
• Academic & Research Centers
• Cancercare Centers
• Others

Regional Analysis

North America is the Leading Region in the Global Cell and Gene Therapy Market

North America is expected to dominate the Global Cell and Gene Therapy Market with 51.1% of global revenue in 2026. Regional leadership is supported by extensive clinical trial activity, advanced healthcare infrastructure, strong biotechnology capabilities, and the presence of numerous cell and gene therapy developers. Significant pharmaceutical investment in CAR-T, gene editing, viral vectors, and manufacturing facilities further strengthens growth. The FDA's supportive regulatory framework encourages development of advanced therapies for serious and rare diseases. Growing personalized medicine adoption and strong academic-industry collaborations are expected to maintain North America's market leadership.

ℹ To learn more about this report – Download Your Free Sample Report Here

Asia Pacific is the Fastest-Growing Region in the Global Cell and Gene Therapy Market

Asia Pacific is projected to register the fastest CAGR of 22.5% through 2035, supported by expanding biotechnology investment and advanced therapy development. China, Japan, South Korea, and India are strengthening clinical trial capabilities, genomic research programs, and cell therapy manufacturing infrastructure. Governments are introducing supportive policies and funding initiatives to accelerate biotechnology innovation and attract international companies. Growing cancer prevalence, increasing diagnosis of genetic disorders, and improving healthcare accessibility are expanding patient demand. Lower manufacturing costs and growing partnerships between regional biotechnology companies and global pharmaceutical manufacturers further strengthen the region's long-term growth prospects.

Europe Cell and Gene Therapy Market

Europe represents a significant share of the Global Cell and Gene Therapy Market, supported by established biotechnology clusters, sophisticated healthcare systems, and extensive academic research capabilities. European research programs, including Horizon initiatives, are supporting innovation in viral vectors, gene editing, regenerative medicine, and advanced therapeutic manufacturing. The region benefits from a highly skilled scientific workforce and strong collaboration between universities, biotechnology companies, pharmaceutical manufacturers, and research institutions. Increasing clinical trials and manufacturing investments are strengthening commercialization capabilities. Regulatory frameworks governing advanced therapy medicinal products continue to shape development while supporting safe introduction of innovative therapies for serious diseases.

Latin America Cell and Gene Therapy Market

Latin America's Cell and Gene Therapy Market is expanding gradually as regional healthcare systems strengthen access to advanced diagnostics, clinical research, and specialized treatment services. Brazil represents the major regional market, supported by its comparatively developed biotechnology ecosystem, research institutions, and large patient population, while Mexico is also strengthening advanced therapy capabilities. Increasing cancer prevalence and diagnosis of genetic disorders are creating demand for innovative treatments. International pharmaceutical and biotechnology companies are increasingly exploring regional clinical trial opportunities. However, limited reimbursement, high treatment costs, specialized manufacturing requirements, and uneven healthcare infrastructure continue to restrict widespread commercial adoption across several countries.

Middle East and Africa Cell and Gene Therapy Market

The Middle East and Africa Cell and Gene Therapy Market remains relatively early in development but offers long-term opportunities as healthcare infrastructure and biotechnology investment expand. Growth is concentrated primarily across Gulf Cooperation Council countries, where governments are investing in precision medicine, genomic research, advanced hospitals, and specialized treatment centers. Saudi Arabia and the UAE are increasingly supporting biotechnology development through national healthcare transformation initiatives. Rising cancer incidence and genetic disease awareness are strengthening demand for innovative therapies. However, high treatment costs, limited local manufacturing capacity, regulatory complexity, and uneven specialist infrastructure continue to constrain broader regional adoption.

The US Cell and Gene Therapy Market

The US Cell and Gene Therapy Market is projected to reach USD 14.2 billion in 2026 and expand at 18.1% CAGR during the forecast period. Growth is supported by extensive clinical research infrastructure, significant biotechnology investment, numerous clinical trials, and continued development of advanced manufacturing technologies. The FDA's regulatory support for innovative therapies targeting serious conditions strengthens commercialization opportunities. Increasing demand for personalized treatments addressing cancer and inherited genetic disorders further supports expansion. However, high development, manufacturing, and treatment costs remain significant barriers, creating reimbursement challenges and restricting patient accessibility to certain advanced cell and gene therapies.

Japan Cell and Gene Therapy Market

Japan's Cell and Gene Therapy Market is expanding rapidly, supported by advanced biomedical research, regenerative medicine capabilities, and a regulatory environment designed to accelerate innovative therapy development. The country has established strong expertise in induced pluripotent stem cells, regenerative medicine, gene therapies, and advanced cellular treatments. Growing cancer incidence and demand for treatments targeting rare genetic disorders are strengthening commercial opportunities. Pharmaceutical and biotechnology companies are expanding research collaborations and clinical programs. Government support for regenerative medicine and streamlined approval pathways further encourages innovation. However, high manufacturing costs, specialized infrastructure requirements, and limited eligible patient populations for certain therapies remain market challenges.

Saudi Arabia Cell and Gene Therapy Market

Saudi Arabia's Cell and Gene Therapy Market is emerging as the country expands precision medicine, genomic research, biotechnology, and specialized healthcare infrastructure under national transformation initiatives. Increasing investment in advanced hospitals, research institutions, genomic programs, and biotechnology manufacturing is creating opportunities for innovative cellular and genetic treatments. Growing cancer burden and identification of inherited genetic disorders are strengthening demand for personalized therapies. Partnerships between international biotechnology companies, healthcare institutions, and domestic research organizations are supporting knowledge transfer and clinical capabilities. However, limited local manufacturing capacity, high therapy costs, specialist workforce requirements, and evolving regulatory pathways currently constrain broader commercialization and patient access.

Regulatory Landscape Analysis

The regulatory landscape is critical to the Cell and Gene Therapy Market as authorities strengthen frameworks addressing safety, efficacy, manufacturing consistency, and long-term patient monitoring. Regulators such as the FDA, EMA, and Japan’s PMDA are developing accelerated pathways for therapies targeting serious, rare, and life-threatening diseases. Increasing regulatory clarity creates opportunities for developers to shorten commercialization timelines and attract investment. However, requirements surrounding gene editing, viral vectors, clinical evidence, and post-treatment surveillance remain complex and costly. Differences between regional regulations can also complicate multinational trials and product launches. Greater harmonization, standardized manufacturing requirements, and clearer guidance for emerging technologies are expected to reduce development uncertainty and support market expansion globally.

Technology Analysis

Technology advancement is fundamentally reshaping the Cell and Gene Therapy Market through improvements in gene editing, cell engineering, vectors, manufacturing, and delivery systems. CRISPR-based platforms, next-generation viral vectors, non-viral delivery technologies, and automated cell-processing systems are improving therapeutic precision and production scalability. Development of allogeneic off-the-shelf therapies creates opportunities to reduce manufacturing time, treatment costs, and logistical complexity compared with patient-specific approaches. Artificial intelligence and advanced analytics are also supporting target identification and manufacturing optimization. However, challenges involving off-target effects, immune responses, vector capacity, and production consistency remain important risks. Continued technological innovation is expected to broaden indications, strengthen clinical outcomes, and accelerate commercialization worldwide.

By Region

North America

• The U.S.
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC

Latin America

• Mexico
• Brazil
• Rest of LATAM

Middle East & Africa

• Saudi Arabia
• The UAE
• South Africa
• Rest of MEA

Competitive Landscape

The Global Cell and Gene Therapy Market is highly competitive, characterized by established pharmaceutical companies, biotechnology innovators, contract development organizations, and academic spin-offs. Leading companies are investing heavily in CAR-T therapies, CRISPR gene editing, viral vectors, stem cell platforms, and allogeneic therapies to strengthen their pipelines. Competition increasingly focuses on improving treatment efficacy, reducing manufacturing costs, shortening production timelines, and expanding therapeutic indications. Strategic collaborations, licensing agreements, acquisitions, and research partnerships remain central to accessing innovative technologies and accelerating commercialization. Companies are also expanding manufacturing facilities and regional clinical trial networks to improve scalability. Emerging biotechnology firms continue challenging established players through specialized platforms. However, regulatory complexity, high development costs, patent competition, and reimbursement pressures significantly influence competitive positioning and long-term market success.

Some of the prominent players in the Global Cell and Gene Therapy Market are:

• Novartis
• Gilead Sciences
• Bristol Myers Squibb
• Johnson & Johnson
• Vertex Pharmaceuticals
• CRISPR Therapeutics
• Sarepta Therapeutics
• BioMarin Pharmaceutical
• Roche
• Pfizer
• Legend Biotech
• Krystal Biotech
• uniQure
• Beam Therapeutics
• Intellia Therapeutics
• Editas Medicine
• Allogene Therapeutics
• Autolus Therapeutics
• Iovance Biotherapeutics
• Sangamo Therapeutics
• REGENXBIO
• Rocket Pharmaceuticals
• Fate Therapeutics
• Cellectis
• Caribou Biosciences
• Prime Medicine
• Sana Biotechnology
• Adaptimmune Therapeutics
• 4D Molecular Therapeutics
• Mesoblast
• Takeda Pharmaceutical
• Amgen
• Bayer
• AstraZeneca
• Biogen
• Ferring Pharmaceuticals
• Arcellx
• Adicet Bio
• Nkarta
• Cabaletta Bio
• Other Key Players

Recent Developments

• July 2026: The FDA expanded approval of Vertex and CRISPR Therapeutics’ Casgevy to patients aged two years and older with sickle cell disease or transfusion-dependent beta thalassemia, significantly broadening pediatric access to gene-editing therapy.
• July 2026: Repligen announced a USD 1.5 billion cash-and-stock acquisition of BioLife Solutions, strengthening its cell therapy manufacturing portfolio with cell-preservation technologies, processing tools, and consumables used across commercial cell therapy production.
• June 2026: The FDA issued draft guidance intended to accelerate cell and gene therapy development by allowing developers to leverage established scientific knowledge, potentially reducing unnecessary testing and improving development efficiency for innovative therapies.
• March 2026: The FDA granted accelerated approval to Rocket Pharmaceuticals’ Kresladi, a gene therapy for severe leukocyte adhesion deficiency-I, marking the first US gene therapy approval of 2026 and expanding treatment options for rare diseases.

Report Details

Report Characteristics
Market Size (2026)	USD 32.5 Bn
Forecast Value (2035)	USD 158.6 Bn
CAGR (2026–2035)	19.3%
The US Market Size (2026)	USD 14.2 Bn
Historical Data	2021 – 2025
Forecast Data	2026 – 2035
Base Year	2025
Segments Covered	By Therapy Type, By Indication, By Delivery Method, and By End User
Regional Coverage	North America – The US and Canada; Europe – Germany, France, The UK, Italy, Spain, Rest of Europe; Asia-Pacific – China, Japan, India, Australia, South Korea, Rest of APAC; Latin America – Mexico, Brazil, Colombia, Argentina, Rest of LATAM; Middle East & Africa – Saudi Arabia, The UAE, South Africa, Rest of MEA